Cell Isolation: Emerging Tech Innovations to Boost Global Industry Revenue
Research Methodologies Followed in this Study -
Primary Research -
Extensive primary research was conducted after acquiring basic knowledge about the global cell isolation market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, CROs, and CMOs, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners.
These interviews were done in five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. About 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This data was gathered using questionnaires, e-mails, online surveys, in-person interviews, and telephone interviews.
Download PDF Brochure - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479
Secondary Research -
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell isolation market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Stem Cell Society Singapore (SCSS), International Society for Advancement of Cytometry (ISAC), and American Filtration and Separations Society (AFS), Food and Drug Administration (FDA), American Society for Cell Biology (ASCB), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Alliance for Regenerative Medicine (ARM), Statista; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others.
These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
End User -
The pharmaceutical & biotechnology companies segment is estimated to register the highest growth rate during the forecast period in the cell isolation market.
Based on end user, the cell isolation market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, and other end users. The pharmaceutical & biotechnology companies segment is estimated to register the highest growth rate during the forecast period. The rising number of biopharmaceutical companies and growing demand for cell-based therapies due to the increasing incidence of chronic diseases such as cancer is anticipated to promote the growth of the pharmaceutical & biotechnology companies segment in coming years.
Geographical Growth Dynamics -
The Asia Pacific region is expected to register highest CAGR during the forecast period of 2024-2029.
Based on the region, the cell isolation market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific is anticipated to register the fastest growth in the cell isolation market owing to the increasing focus on the development of cell-based therapies, government initiatives for infrastructural improvements of healthcare facilities, growing funding for R&D, and the booming healthcare sector. Due to their large and growing populations, India and China are expected to be the key growth hotspots in the Asia Pacific market. Over the last decade, CMOs in the Asia Pacific region have impacted the global pharmaceutical manufacturing market. Several small- and medium-scale CMOs set up in the Asia Pacific region have obtained US FDA approval for their operations and completed GMP certifications, thus driving the region’s cell isolation market.
Request Sample Pages - https://www.marketsandmarkets.com/requestsampleNew.asp?id=103931479
Key Players -
Key players in the cell isolation market include Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), BD (US), Agilent Technologies, Inc. (US), Miltenyi Biotec (Germany), Revvity (US), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Lonza (Switzerland), QIAGEN (Netherlands), ALFA LAVAL (Sweden), Terumo Corporation (Japan), Corning Incorporated (US), Bio-Rad Laboratories, Inc. (US), GenScript (US), Bio-Techne (US), Takara Bio Inc. (Japan), Standard BioTools (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), and STEMCELL Technologies (Canada).